Bookmark and Share


Nicholas P. Ambulos, Jr., PhD, Director

Dr. Nicholas Ambulos has been director of the Biopolymer Core Facility since 1993. He has an extensive background in molecular biology and molecular microbiology. He is fully familiar with all aspects of DNA and RNA synthesis, DNA sequencing, genotyping, peptide synthesis, and more recently has become exceedingly familiar with gene expression technologies. Dr. Ambulos has co-authored a number of manuscripts relating to peptide synthesis chemistry and analysis, and was responsible for the synthesis and purification of the three peptides that comprise the NIST Reference Material #8327, "Peptide Standards for Molecular Mass and Purity Measurements". More recently, Dr. Ambulos has coauthored manuscripts relating to gene expression studies.

Dr. Ambulos is responsible for introducing new investigators to the facility, by providing detailed descriptions of the services offered, and introducing investigators to the staff members responsible for these services. After initial consultations regarding specific projects, the investigators are encouraged to interact directly with the staff members that will be supporting their research projects. Dr. Ambulos is responsible for the educational component of the core, arranging to host research and technical seminars, as well as presenting the Facility's capabilities at Departmental meetings.

As part of his role as facility director, Dr. Ambulos is responsible for acquiring state of the art instrumentation and identifying new areas of service. He has been successful in securing NIH Shared Instrumentation Grants with which to purchase new instrumentation. He has also taken advantage of the State of Maryland's Revolving Equipment Loan Program, whereby the State purchases an instrument for the facility, and the facility repays the loan with modest interest. In addition to his role as the director of the Biopolymer/Genomics Core Facility, Dr. Ambulos has also served as the Director of Shared Services for the Marlene and Stewart Greenebaum Cancer Center since 2004. In this role, Dr. Ambulos provides guidance to other shared service directors to ensure that the services offered are effective and strengthen the mission of the Greenebaum Cancer Center. Dr. Ambulos works with shared service directors and Ms. Susan Myers, Director of Finance, to prepare realistic and cost-effective budgets for each of the shared services.

Jin Yin, DDS, Laboratory Supervisor

Dr. Yin was hired in 2004 to support the Biopolymer/Genomics Core Facility's gene expression and high through put genotyping services. Dr. Yin has over 10 years experience in methods development for microarray technology. This includes developing optimal methods for the extraction of high quality RNA from cell culture, tissue, and more importantly, from small biopsy samples. She has also optimized methods for printing custom cDNA and oligonucleotides arrays, and has extensive experience preparing labeled cRNA, hybridizing, washing and scanning arrays. She has coauthored numerous manuscripts related to microarrays, genotyping and gene expression analysis. Dr. Yin provides consulting services for investigators who want to initiate gene expression or genotyping studies.

Li Tang, Research Specialist

Ms. Tang joined th Biopolymer/Genomics Core Facilityin January 2009. She has more than five years experience in automated DNA sequencing gene expression array technology and genotyping. Ms. Tang is responsible for gene expression services using both our Affymetrix GeneChip technology. Ms. Tang has co-authored a number of manuscripts based on gene expression and DNA sequencing.

Kevin Rossomando, Lab Assistant

Mr. Rossomando has been a member of the Biopolymer/Genomics Core Facility since 1997. He was responsible for the DNA/RNA synthesis service until July 2010, when the facility terminated this service. He has also provided critical support to the DNA sequencing service during his tenure here. Currently, he is responsible for oversight of the DNA sequencing service and provides a conduit between our customers and the commercial vendors with whom we have established contracts, to meet the DNA synthesis needs of our investigators.